Ricky Hsu, MD
Internal Medicine · New York, NYNPI 1568491967
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $765,635 of the $1,027,900 with a category attached, or 74.5%. Viiv Healthcare Company accounts for 64.6% of it on its own, with 38 other manufacturers making up the rest. Among internal medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,532 payments — averaging $670.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$664K
- Janssen Products, LP$105K
- Merck$84K
- Gilead$77K
- EMD Serono, Inc.$72K
- Janssen Scientific Affairs, LLC$8K
- plus $18K from 33 others
Across 76 payments — averaging $2608.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Viiv Healthcare Company$99K
- Gilead$53K
- Janssen Research & Development, LLC$36K
- GSK$10K
What the payments were for
- Consulting fees$110,93311%
- Speaking & faculty fees$765,63574%
- Travel & lodging$115,93211%
- Food & beverage$34,7553%
- Education$6450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,027,900 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SerostimSomatropin | 47 | $1,214,053 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 269 | $1,113,098 |
| RukobiaFostemsavir Tromethamine | 48 | $427,860 |
| CabenuvaCabotegravir/Rilpivirine | 66 | $403,371 |
| Egrifta SvTesamorelin Acetate | 55 | $389,192 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 80 | $360,128 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 89 | $356,795 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 73 | $337,852 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 68 | $254,093 |
| TivicayDolutegravir Sodium | 109 | $247,573 |
| DovatoDolutegravir Sodium/Lamivudine | 79 | $232,355 |
| DescovyEmtricitabine/Tenofov Alafenam | 110 | $232,320 |
| PifeltroDoravirine | 90 | $159,444 |
| JulucaDolutegravir/Rilpivirine | 33 | $113,755 |
| Maraviroc | 89 | $73,436 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyRukobia, Cabenuva, Triumeq, Tivicay, Dovato | $663,707 | $1,781,709424 claims |
| GileadBiktarvy, Descovy, Genvoya | $76,769 | $1,392,425391 claims |
| EMD Serono, Inc.Serostim | $72,088 | $1,214,05347 claims |
| Theratechnologies Inc.Egrifta Sv | $8,277 | $389,19255 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $127 | $360,12880 claims |
| Janssen Products, LPSymtuza | $104,816 | $337,85273 claims |
| MerckPifeltro, Isentress, Januvia | $83,736 | $236,003151 claims |
| Johnson & JohnsonPrezcobix, Xarelto | $1,531 | $76,71164 claims |
| Novo NordiskOzempic, Rybelsus | $20 | $76,25269 claims |
| AstraZenecaFarxiga | $217 | $27,81750 claims |
| Antares Pharma, Inc.Xyosted | $153 | $22,08236 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $123 | $20,21614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in New York
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- James UnderbergNew York$953K
- Terry PlasseNew York$883K
- Krisczar BungayNew York$554K
- Eytan SteinNew York$496K
- Larry NeumanNew York$457K
- Wuhua JingNew York$338K
- Harvey SchneienNew York$334K
- Louis AronneNew York$316K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.